<DOC>
	<DOCNO>NCT01903720</DOCNO>
	<brief_summary>This study evaluate safety efficacy OZURDEX® ( 700 µg dexamethasone implant ) patient macular edema associate branch retinal vein occlusion .</brief_summary>
	<brief_title>A Safety Efficacy Study OZURDEX® Macular Edema Associated With Branch Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis macular edema Best correct visual acuity approximately 20/400 20/40 study eye Use systemic steroid ( eg , oral , intravenous , intramuscular , epidural , rectal , extensive dermal ) within 1 month Intraocular surgery , include cataract surgery , and/or laser surgery type within 3 month Any active ocular infection either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>